Is Your Telehealth Platform Scaring Patients Away?

Design is the overlooked moat in digital health

Dec 16 • Ashwin Sharma, MD

5

November 2025

When Science Fails, and Startups Fly

Novo has cause to be disheartened, while Function Health and GLP-1 consumers in India do not

Nov 25 • Ashwin Sharma, MD

18

2

Trump's announcement shifts competition in the GLP-1 market

Who will benefit, and who won’t?

Nov 11 • Ashwin Sharma, MD

18

1

3

Why Can't Anyone Stop Compounded GLP-1s?

Because federal, legal, and private forces won't allow it

Nov 2 • Ashwin Sharma, MD

25

3

6

September 2025

What Comes After the GLP-1 Hype?

It's messy, unglamorous stuff involving patients and insurers and crystal balls for pharma

Sep 28 • Ashwin Sharma, MD

20

5

3

When GLP-1s become brain drugs

Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?

Sep 14 • Ashwin Sharma, MD

30

3

3

Why Novo Nordisk and Eli Lilly Won't Compete on Price

But they will compete on market access and launch success

Sep 1 • Ashwin Sharma, MD

21

5

6

August 2025

The $100 Billion Overreaction

how do oral GLP-1s expand the market?

Aug 24 • Ashwin Sharma, MD

17

4

Why Britain’s GLP-1 Patients Are Paying for America’s Drug Politics

1.5 million become collateral damage

Aug 17 • Ashwin Sharma, MD

12

3

1

Why Novo Nordisk is Out of Options (Except One)

patents become weapons

Aug 5 • Ashwin Sharma, MD

37

23

7

July 2025

Are GLP-1s About to Kill the Alcohol Industry?

Change is definitely coming, but not in the way you think

Jul 13 • Ashwin Sharma, MD

14

2

GLP-1s Are Quietly Killing Your Cravings (and Maybe Your Bad Habits Too)

New brain-imaging studies reveal these meds may silence the impulse engine driving addiction, compulsive behaviours, and billion-dollar snack aisles

Jul 6 • Ashwin Sharma, MD

96

8

13